Tamar H. Taddei

8.3k total citations · 4 hit papers
159 papers, 4.3k citations indexed

About

Tamar H. Taddei is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Tamar H. Taddei has authored 159 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Hepatology, 101 papers in Epidemiology and 30 papers in Surgery. Recurrent topics in Tamar H. Taddei's work include Liver Disease Diagnosis and Treatment (93 papers), Liver Disease and Transplantation (64 papers) and Hepatocellular Carcinoma Treatment and Prognosis (48 papers). Tamar H. Taddei is often cited by papers focused on Liver Disease Diagnosis and Treatment (93 papers), Liver Disease and Transplantation (64 papers) and Hepatocellular Carcinoma Treatment and Prognosis (48 papers). Tamar H. Taddei collaborates with scholars based in United States, United Kingdom and Germany. Tamar H. Taddei's co-authors include David E. Kaplan, Nadim Mahmud, David S. Goldberg, Marina Serper, Amit G. Singal, Rajni Mehta, Binu V. John, Ayse Aytaman, Kristel Hunt and Janice H. Jou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Tamar H. Taddei

155 papers receiving 4.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

2023 740 citations Tamar H. Taddei et al. Hepatology profile →
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

2019 233 citations George N. Ioannou, Lauren A. Beste et al. Gastroenterology profile →
AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis

2024 63 citations Tamar H. Taddei et al. Hepatology profile →
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis

2024 44 citations Tamar H. Taddei et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamar H. Taddei United States	33	2.7k	2.4k	715	515	350	159	4.3k
David E. Kaplan United States	37	3.0k 1.1×	2.6k 1.1×	973 1.4×	497 1.0×	400 1.1×	194	4.8k
Simone I. Strasser Australia	38	2.9k 1.1×	2.7k 1.1×	728 1.0×	349 0.7×	184 0.5×	198	4.3k
Gary P. Jeffrey Australia	32	2.3k 0.8×	2.5k 1.1×	638 0.9×	237 0.5×	415 1.2×	138	4.5k
Patrick Hillon France	37	2.7k 1.0×	3.0k 1.2×	1.2k 1.6×	732 1.4×	568 1.6×	137	5.5k
Sarah Berhane United Kingdom	20	2.5k 0.9×	1.9k 0.8×	654 0.9×	756 1.5×	358 1.0×	41	4.2k
S. Fagiuoli Italy	40	3.6k 1.3×	3.1k 1.3×	1.3k 1.8×	474 0.9×	336 1.0×	231	5.7k
Dong Hyun Sinn South Korea	41	3.5k 1.3×	3.3k 1.4×	1.5k 2.1×	812 1.6×	382 1.1×	272	5.9k
Ryutaro Hirose United States	36	2.2k 0.8×	1.4k 0.6×	2.4k 3.4×	537 1.0×	289 0.8×	140	4.9k
David S. Goldberg United States	41	3.8k 1.4×	2.8k 1.2×	2.8k 3.9×	432 0.8×	303 0.9×	257	6.2k
Stuart McPherson United Kingdom	32	3.2k 1.2×	5.3k 2.2×	902 1.3×	191 0.4×	522 1.5×	139	6.2k

Countries citing papers authored by Tamar H. Taddei

Since Specialization

Citations

This map shows the geographic impact of Tamar H. Taddei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamar H. Taddei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamar H. Taddei more than expected).

Fields of papers citing papers by Tamar H. Taddei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamar H. Taddei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamar H. Taddei. The network helps show where Tamar H. Taddei may publish in the future.

Co-authorship network of co-authors of Tamar H. Taddei

This figure shows the co-authorship network connecting the top 25 collaborators of Tamar H. Taddei. A scholar is included among the top collaborators of Tamar H. Taddei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamar H. Taddei. Tamar H. Taddei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Nicole J., Muyi Li, Philip Vutien, et al.. (2025). Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening. Gastroenterology. 170(3). 606–618. 1 indexed citations

Njei, Basile, Catherine Mezzacappa, Binu V. John, et al.. (2025). Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases and Sciences. 70(2). 802–813. 3 indexed citations

John, Binu V., Dustin Bastaich, Catherine Mezzacappa, et al.. (2025). Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal of Gastroenterology. 120(11). 2583–2591. 2 indexed citations

Gordon, Kirsha S., Janet P. Tate, Joseph K. Lim, et al.. (2024). Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open. 7(11). e2443608–e2443608. 4 indexed citations

Vutien, Philip, Nicole J. Kim, Andrew M. Moon, et al.. (2024). Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology. 82(2). 422–437. 4 indexed citations

Skanderson, Melissa, Farah Kidwai‐Khan, Dena M. Carbonari, et al.. (2024). Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications. 8(7). 5 indexed citations

Serper, Marina, et al.. (2024). Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes. The American Journal of Gastroenterology. 120(9). 2059–2071. 2 indexed citations

Thompson, Rachel, Tamar H. Taddei, David E. Kaplan, & Anahita Rabiee. (2024). Safety of naltrexone in patients with cirrhosis. JHEP Reports. 6(7). 101095–101095. 11 indexed citations

Re, Vincent Lo, Craig Newcomb, Dena M. Carbonari, et al.. (2024). Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology and Drug Safety. 33(12). e70069–e70069. 1 indexed citations

10.

John, Binu V., Raphaella Ferreira, David E. Kaplan, et al.. (2022). Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal of Hepatology. 77(5). 1349–1358. 18 indexed citations

11.

John, Binu V., A. Sidney Barritt, Andrew M. Moon, et al.. (2022). Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastroenterology and Hepatology. 20(10). 2405–2408.e3. 6 indexed citations

12.

Mahmud, Nadim, et al.. (2022). Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal of Hepatology. 76(5). 1100–1108. 26 indexed citations

13.

Allara, Elias, Tadaaki Arizumi, Dominik Bettinger, et al.. (2020). Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer. 124(2). 407–413. 17 indexed citations

14.

Do, Albert, Denise Esserman, Supriya Krishnan, et al.. (2020). Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal of General Internal Medicine. 35(7). 2025–2034. 22 indexed citations

15.

Kaplan, David E., Marina Serper, Binu V. John, et al.. (2020). Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. Clinical Gastroenterology and Hepatology. 19(10). 2148–2160.e14. 42 indexed citations

16.

Rentsch, Christopher T., Farah Kidwai‐Khan, Janet P. Tate, et al.. (2020). Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Medicine. 17(9). e1003379–e1003379. 234 indexed citations

17.

Mahmud, Nadim, et al.. (2019). Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 104(1). 104–112. 16 indexed citations

18.

Mahmud, Nadim, David E. Kaplan, Tamar H. Taddei, & David S. Goldberg. (2019). Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology. 69(5). 2150–2163. 123 indexed citations

19.

Kaplan, David E., Rajni Mehta, Kathryn D’Addeo, T. Gade, & Tamar H. Taddei. (2018). Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal of Vascular and Interventional Radiology. 29(4). 540–549.e4. 7 indexed citations

20.

Kaplan, David E., Feng Dai, Ayse Aytaman, et al.. (2015). Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology and Hepatology. 13(13). 2333–2341.e6. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact